Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACT001 plus whole-brain radiotherapy for lung cancer brain metastases
ChiCTR2300069129Phase 2Not yet recruiting
- Sponsor
- Shandong Cancer Hospital
- Start
- Sep 2022
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of dimethylaminomicheliolide in bronchial carcinoma (2 arms), sponsored by Shandong Cancer Hospital. Primary endpoint: Objective response rate of intracranial tumor within 3 months. Planned start Sep 2022; status: not yet recruiting.
02
Drugs
dimethylaminomicheliolide
03
Conditions
bronchial carcinoma
Beyond the preview
Go deeper on ChiCTR2300069129.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300069129.